<< Back to News

System Formulary Update
Meningococcal Group B and Group ACWY Vaccines Standardization

Situation

The Meningococcal Vaccines (Group B and Group ACWY vaccines) class review and formulary standardization was approved at the April 2022 System Pharmacy and Therapeutics Committee meeting.

Background/Assessment

The following medications were reviewed: Menactra® (MenACWY-D), Menveo® (MenACWY-CRM), MenQuadfi (MenACWY-TT), Bexsero (MenB-4C), and Trumenba® (MenB-FHbp).

The CDC considers the MenACWY vaccines to be interchangeable; patients may receive a combination of vaccine products to complete the recommended series. The MenB vaccines are not interchangeable; the same vaccine product must be used to complete the vaccine series.

Menactra® is being discontinued by the manufacturer (SanofiPasteur) and will be phased out of the market in mid-2022. Menveo® is already on formulary at select System entities; unlike Menactra, Menveo® is supplied in separate vials (lyophilized MenA, liquid MenCWY) which must be mixed together for administration. The products require the same volume for administration (0.5 mL) and are given intramuscularly.

Recommendations

Changes Effective: Tuesday, June 28^th

System P&T voted to include the following products on the UNC Health System Drug Formulary:

• Menveo® (meningococcal vaccine ACWY IM kit; 10 mcg-5mcg/0.5 mL)
• Bexsero (meningococcal vaccine 25 mcg/0.5 mL syringe)

As a result, the following products will be removed from the inpatient drug formulary:

• Menactra® (meningococcal vaccine ACWY IM solution; 4 mcg/0.5 mL )